FibroBiologics (FBLG) Change in Accured Expenses (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Change in Accured Expenses of $971000.0 for Q2 2026, up 152.86% year-over-year from $384000.0 in Q2 2025, and up 1122.11% on a QoQ basis from -$95000.0 in Q1 2026.
FibroBiologics (FBLG) Change in Accured Expenses (2023 - 2026) Analysis & Trends
FibroBiologics has reported Change in Accured Expenses for 4 years, with the latest figure at $971000.0 in Q2 2026.
- Change in Accured Expenses for Q2 2026 came in at $971000.0, up 152.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $20000.0 (down 97.63% YoY), and the FY2025 annual result was -$1.5 million, down 219.87% from the prior year.
- Change in Accured Expenses grew to $971000.0 in Q2 2026, from -$95000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.5 million in Q4 2024 and troughed at -$1.0 million in Q1 2025.
- A 4-year average of $92714.3 and a median of $87000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The widest annual swing landed in 2024, when Change in Accured Expenses soared 1813.04%; it then plunged 2424.14% in 2025.
- A 4-year view of Change in Accured Expenses shows it stood at $275000.0 in 2023, then surged by 452.0% to $1.5 million in 2024, then slumped by 108.17% to -$124000.0 in 2025, then soared by 883.06% to $971000.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $971000.0 in Q2 2026, -$95000.0 in Q1 2026, and -$124000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | 971,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 971,000.00 |
| Jun 30, 2026 | 971,000.00 |
| Mar 31, 2026 | -95,000.00 |
| Mar 31, 2026 | -95,000.00 |
| Dec 31, 2025 | -124,000.00 |
| Dec 31, 2025 | -124,000.00 |
| Sep 30, 2025 | -732,000.00 |
| Sep 30, 2025 | -732,000.00 |
| Jun 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 384,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | -29,000.00 |
| Sep 30, 2024 | -29,000.00 |
| Jun 30, 2024 | 394,000.00 |
| Jun 30, 2024 | 394,000.00 |
| Mar 31, 2024 | -630,000.00 |
| Mar 31, 2024 | -630,000.00 |